Search Results

Medidata today announced it has renewed its relationship with the PPD clinical research business of Thermo Fisher Scientific Inc.

The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, has been selected by the Biomedical Advanced Research and Development Authority (BARDA) to implement the first BARDA-supported Phase II platform clinical trial to investigate multiple therapeutic options for the treatment of acute respiratory distress syndrome (ARDS).

The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, unveiled a new clinical research laboratory building at its good manufacturing practices lab in Middleton, Wisconsin.

Curio Digital Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has granted clearance to MamaLift PlusTM.

The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, announced the expansion of its central laboratory operations in Kentucky dedicated to accelerating pharmaceutical and biotech customers’ delivery of safe, effective medicines to patients.

Lipocine Inc. today announced positive topline study results demonstrating bioequivalence of LPCN 1154 to IV brexanolone in an NDA enabling pivotal pharmacokinetic (PK) study. Lipocine is developing LPCN 1154, oral brexanolone, for the treatment of postpartum depression (PPD).

The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, is embracing the theme of the 60th annual Drug Information Association (DIA) annual meeting today in San Diego – “Charting New Horizons.”

Biogen Inc. and Sage Therapeutics, Inc. announced ZURZUVAE™ 50 mg CIV is now available by prescription for the treatment of postpartum depression for adults in the United States, with product already at specialty pharmacies and delivered to patients.

Thermo Fisher Scientific’s PPD Clinical Research Business Selected to Support National Cancer Institute’s Cancer Trials Support Unit.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has completed its acquisition of PPD, Inc. (Nasdaq: PPD), a leading global provider of clinical research services to the biopharma and biotech industry, for $17.4 billion.